ArticleThe journal of allergy and clinical immunology. Global2023

ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial.

Pedro Giavina-Bianchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.